Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.